Alpha Healthcare Acquisition Corp. (AHAC)
Upgrades & Downgrades
Latest AHAC news
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp...
26 August 2021
DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on ...
4 August 2021
NEW YORK and DURHAM, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that it has filed a defi...
EXCLUSIVE: Humacyte, Alpha Healthcare CEOs Talk SPAC Deal, Technology, Trials On 'SPACs Attack'
25 May 2021
Humacyte is set to go public via the special purpose acquisition company Alpha Healthcare Acquisition Corp (NASDAQ: AHAC) in a deal that values the company at around $800 million. Humacyte founder an...
2 SPAC Stocks That Could Be 10-Baggers
14 March 2021
They could even deliver greater gains than just a 10-times return.
Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX...
5 March 2021
DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, toda...
Humacyte: Disrupting The Organ Transplant Industry
26 February 2021
Humacyte has a platform technology allowing for the mass production of human organs and blood vessels within a laboratory. Its products are superior as they can be stored for over a year, pose little ...
Why Humacyte Is Going Public Via SPAC
17 February 2021
Feb.17 -- Dr. Laura Niklason, chief executive officer and founder of Humacyte, discusses the biotech company's decision to go public through a merger with Alpha Healthcare Acquisition Corp., a special...